TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11874388

Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: mizolastine 10 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 10519674

Group type: EXPERIMENTAL
Intervention: Glucose, insulin and potassium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study: 7805253

Group type: EXPERIMENTAL
Intervention: Primary PTCA
Number of subjects: 8496

Group type: COMPARATOR
Intervention: Thrombolysis and PTCA
Number of subjects: 8496

Group type: COMPARATOR
Intervention: Thrombolysis and PTCA (routine strategy)
Number of subjects: 8496
Study: 2127257

Group type: EXPERIMENTAL
Intervention: Oral flurbiprofen (150 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 8
Study: 30203677

Group type: EXPERIMENTAL
Intervention: Home‐based Individually tailored Physical activity Print (HIPP) intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Wellness contact control
Number of subjects: 84
Study: 31547377

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (3200 IU per day for five weeks before surgery)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (vegetable oil during the same time)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rehabilitation and supplementation
Number of subjects: 33
Study: 27443171

Group type: EXPERIMENTAL
Intervention: Capsinoid ingestion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 0
Study: 25160845

Group type: EXPERIMENTAL
Intervention: Reduced calorie weight loss diet (n = 118)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Moderate‐ to vigorous‐intensity aerobic exercise (n = 117)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Combination of diet and exercise (n = 117)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control (n = 87)
Number of subjects: 439
Study: 23915267

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (organizational and training for professionals)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 15
Study: 21839884

Group type: EXPERIMENTAL
Intervention: Dyspepsia (functional or organic)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Functional dyspepsia
Number of subjects: 850

Group type: COMPARATOR
Intervention: Organic dyspepsia
Number of subjects: 850
Study: 19131655

Group type: EXPERIMENTAL
Intervention: Prearrival communication via fax and telephone call to patient/surrogate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no prearrival communication)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Successful prearrival communications
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intervention (ranitidine infusion during flight)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Recruitment initiation on arrival
Number of subjects: 100
Study: 17380181

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15025614

Group type: EXPERIMENTAL
Intervention: 90-min application of Lidocaine/Prilocaine cream followed by a 30-min interval before cannulation (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 60-min application of Lidocaine/Prilocaine cream followed by immediate cannulation (Group A)
Number of subjects: 60
Study: 11561265

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous morphine patient-controlled analgesia (PCA)
Number of subjects: 18
Study: 9749274

Group type: EXPERIMENTAL
Intervention: rtPA (recombinant tissue plasminogen activator) administered at the pick-up point
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Primary angioplasty performed in hospital
Number of subjects: 1200
Study: 7848592

Group type: EXPERIMENTAL
Intervention: Octreotide (100, 200, and 300 micrograms subcutaneously every 8 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High doses of loperamide and diphenoxylate orally plus placebo subcutaneously for 10 days
Number of subjects: 20
Study: 3228575

Group type: EXPERIMENTAL
Intervention: Tablet B (MOTRIN Tablet) 400 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tablet A (generic ibuprofen tablet) 400 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both Tablet A and Tablet B
Number of subjects: 12
Study: 5448798

Group type: EXPERIMENTAL
Intervention: Iron therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (baseline assessment before treatment)
Number of subjects: 47
Study: 29121401

Group type: EXPERIMENTAL
Intervention: MP29-02 (azelastine hydrochloride and fluticasone propionate)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AZE + FP
Number of subjects: 28
Study: 29231508

Group type: EXPERIMENTAL
Intervention: Acupuncture anesthesia (needles retained for 10 min after tooth extraction)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Drug local block anesthesia (compound articaine hydrochloride injection)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Acupuncture and Drug)
Number of subjects: 60
Study: 26629707

Group type: EXPERIMENTAL
Intervention: Training program based on letter-speech sound associations, 34 individual sessions of 45 minutes over five months.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 44
Study: 23969184

Group type: EXPERIMENTAL
Intervention: Octreotide implant (84 mg)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Octreotide LAR (10-40 mg)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Octreotide implant
Number of subjects: 163

Group type: COMPARATOR
Intervention: Octreotide LAR
Number of subjects: 163
Study: 20436711

Group type: EXPERIMENTAL
Intervention: Clevudine (30 mg once daily)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Lamivudine (100 mg once daily)
Number of subjects: 116
Study: 18486741

Group type: EXPERIMENTAL
Intervention: ASC plus chemotherapy (MVP and vinorelbine combined)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: ASC plus vinorelbine
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: ASC plus MVP
Number of subjects: 409

Group type: COMPARATOR
Intervention: ASC alone
Number of subjects: 409
Study: 16813181

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with microorganism pharmaceutical preparations (Group A)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Oral administration of medicine for loosening the bowel to relieve constipation plus microorganism pharmaceutical preparations (Group B)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Simple acupuncture (Group C)
Number of subjects: 95
Study: 15023641

Group type: EXPERIMENTAL
Intervention: 0.12% Na + 0.00% CDG sausage
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 0.12% Na + 0.10% CDG sausage
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 0.12% Na + 0.40% CDG sausage
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 0.69% Na + 0.00% CDG sausage
Number of subjects: 65
Study: 11139979

Group type: EXPERIMENTAL
Intervention: Tilt table testing with noninvasive brain and skeletal muscle oximetry in patients with syncope.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tilt table testing in healthy volunteers.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tilt table testing with simultaneous assessment of brain and skeletal muscle oxygenation.
Number of subjects: 24
Study: 8975684

Group type: EXPERIMENTAL
Intervention: Edge-assignment in contour matching task
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Deliberate attention to one region of an ambiguous figure-ground display
Number of subjects: 8
Study: 1291185

Group type: EXPERIMENTAL
Intervention: Xylitol gum
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sorbitol gum
Number of subjects: 28

Group type: COMPARATOR
Intervention: No chewing phase (Control)
Number of subjects: 28
Study: 6379505

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol 320 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol 80 mg/d
Number of subjects: 0
Study: 29431228

Group type: EXPERIMENTAL
Intervention: MAS063DP lotion
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0.02% triamcinolone acetonide lotion
Number of subjects: 16
Study: 26607831

Group type: EXPERIMENTAL
Intervention: Sodium butyrate enemas (30ml of sodium butyrate 600mmol/L, b.i.d. for 30 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (placebo, b.i.d. for 30 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium butyrate enemas
Number of subjects: 20
Study: 23659682

Group type: EXPERIMENTAL
Intervention: Occupation-focused family intervention
Number of subjects: 30
Study: 22370739

Group type: EXPERIMENTAL
Intervention: Capadenoson 10 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Capadenoson 20 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Capadenoson (various doses)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Capadenoson
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 19640572

Group type: EXPERIMENTAL
Intervention: Single-dose Change
Number of subjects: 160

Group type: COMPARATOR
Intervention: No change
Number of subjects: 160
Study: 17851565

Group type: EXPERIMENTAL
Intervention: Baicalin (50 mg tablets, three times daily for 14 days)
Number of subjects: 18
Study: 15681300

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg twice daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Losartan (50 mg twice daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bradykinin (30 to 300 pmol/min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Norepinephrine (60 to 540 pmol/min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lys-des-Arg9-bradykinin (1 to 10 nmol/min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lys-[Leu8]-des-Arg9-bradykinin (1 to 10 nmol/min)
Number of subjects: 11
Study: 12832973

Group type: EXPERIMENTAL
Intervention: Hilar dissection (G1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 'Glissonean' approach and stapling of the pedicle (G2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 80
Study: 10511131

Group type: EXPERIMENTAL
Intervention: Doxazosin (1 mg o.d. for 3 days, followed by 2 mg o.d. for 7 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8895264

Group type: EXPERIMENTAL
Intervention: HBOC-201 (3 mL/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: HES (6%)
Number of subjects: 13
Study: 2049684

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once daily
Number of subjects: 78

Group type: COMPARATOR
Intervention: Nitrendipine 10 mg bid
Number of subjects: 78
Study: 6509877

Group type: EXPERIMENTAL
Intervention: Combination tablet containing triprolidine hydrochloride and pseudoephedrine hydrochloride
Number of subjects: 19

Group type: COMPARATOR
Intervention: Syrup containing triprolidine hydrochloride and pseudoephedrine hydrochloride
Number of subjects: 19

Group type: COMPARATOR
Intervention: Single-ingredient tablet of pseudoephedrine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Single-ingredient tablet of triprolidine
Number of subjects: 19
Study: 31011266

Group type: EXPERIMENTAL
Intervention: Green Gloo adhesive
Number of subjects: 18

Group type: COMPARATOR
Intervention: Transbond XT adhesive
Number of subjects: 18
Study: 28918732

Group type: EXPERIMENTAL
Intervention: Acupuncture alone (177 patients)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Acupuncture plus pharmacotherapy (178 patients)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Pharmacotherapy alone (173 patients)
Number of subjects: 528
Study: 25942472

Group type: EXPERIMENTAL
Intervention: Reduced Glycerin Vaginal Formulation (RGVF) gel - 7 daily doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rectal Specific Formulation (RF) gel - 7 daily doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo - 6 daily doses followed by 1 dose of Vaginal Formulation (VF) gel
Number of subjects: 0
Study: 23651713

Group type: EXPERIMENTAL
Intervention: Irbesartan (ARB)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 21478476

Group type: EXPERIMENTAL
Intervention: Fully-branded female packs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plain packs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-female branded packs
Number of subjects: 0
Study: 19222623

Group type: EXPERIMENTAL
Intervention: Daptomycin 4 mg/kg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vancomycin according to standard of care
Number of subjects: 0
Study: 17139034

Group type: EXPERIMENTAL
Intervention: Adherence therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 0
Study: 12624483

Group type: EXPERIMENTAL
Intervention: BT‐CoQ10 (300 mg daily for 1 week)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Commercial grade CoQ10 (300 mg daily for 1 week)
Number of subjects: 11
Study: 11516000

Group type: EXPERIMENTAL
Intervention: Endopore dental implants
Number of subjects: 50
Study: 9145132

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (100% oxygen at 2.4 ATA, n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (8.75% oxygen at 2.4 ATA, n = 6)
Number of subjects: 12
Study: 8198274

Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous lidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 mg/kg intravenous lidocaine
Number of subjects: 0
Study: 3542470

Group type: EXPERIMENTAL
Intervention: Cefazoline (Kefzol 0.5 g every six hours)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Ceftriaxone (Rocephin 2 g single dose)
Number of subjects: 541
Study: 30241227

Group type: EXPERIMENTAL
Intervention: Adjuvant carboplatin and paclitaxel chemotherapy followed by radiotherapy
Number of subjects: 146
Study: 27006549

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg intravenously
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Butorphanol 1 mg intravenously
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline 3 ml intravenously (placebo)
Number of subjects: 90
Study: 25284808

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 3426

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 3426

Group type: EXPERIMENTAL
Intervention: Moderate renal insufficiency (RI)
Number of subjects: 3426
Study: 23900091

Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac sodium hydrate eye drops, 2 times/day for 10 days (low myopia) or 14 days (high myopia)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac sodium hydrate eye drops
Number of subjects: 74

Group type: COMPARATOR
Intervention: 0.1% fluorometholone eye drops, 4 times/day for 16 days
Number of subjects: 74
Study: 21518967

Group type: EXPERIMENTAL
Intervention: Salmonella typhii vaccination
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: ADMA levels
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Interleukin 6 levels
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: ADMA and interleukin 6 correlation
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: ADMA and interleukin 6 levels
Number of subjects: 351
Study: 17985084

Group type: EXPERIMENTAL
Intervention: Preemptive warfarin dose reduction (10‐20%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No change in warfarin dosing (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preemptive warfarin dose reduction (10‐20%) with TMP‐SMX
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preemptive warfarin dose reduction (10‐20%) with levofloxacin
Number of subjects: 40
Study: 16513130

Group type: EXPERIMENTAL
Intervention: Children who experienced the event four times with consistent suggestions
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Children who experienced the event four times with inconsistent suggestions
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group of children who experienced the event just one time
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Children encouraged to identify the source of false suggestions
Number of subjects: 130
Study: 12679925

Group type: EXPERIMENTAL
Intervention: alpha 2b interferon (3 MU/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Routine drugs (VitC, aspartic acid)
Number of subjects: 48
Study: 10878680

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (30 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8992906

Group type: COMPARATOR
Intervention: Conventional intubation (group KL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Trachlight intubation (group TT)
Number of subjects: 120
Study: 1400985

Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza B reassortant virus vaccine (doses ranging from 10(3.2) to 10(6.2) TCID50)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza B reassortant virus vaccine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Unvaccinated control group
Number of subjects: 63
Study: 2943685

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 29133606

Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass plus medical therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 100
Study: 26931364

Group type: EXPERIMENTAL
Intervention: Ottawa Statement on the Ethical Design and Conduct of Cluster‐Randomized Trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster-randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethical analysis using the Ottawa Statement
Number of subjects: 0
Study: 24885976

Group type: EXPERIMENTAL
Intervention: SAIA intervention (implemented for six months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison facilities (no intervention)
Number of subjects: 36
Study: 22386831

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/400 mg BID, 400 mg once daily
Number of subjects: 3588

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg daily
Number of subjects: 3588

Group type: EXPERIMENTAL
Intervention: Celecoxib 800 mg daily
Number of subjects: 3588

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin use
Number of subjects: 3588

Group type: EXPERIMENTAL
Intervention: Age ≥65 years
Number of subjects: 3588
Study: 20299258

Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate
Number of subjects: 0
Study: 18545189

Group type: EXPERIMENTAL
Intervention: Elastic resistance training (ERT) plus usual TKD training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group receiving usual TKD training only
Number of subjects: 12
Study: 17135986

Group type: EXPERIMENTAL
Intervention: COMB (fluoxetine + cognitive-behavioral therapy)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: FLX (fluoxetine)
Number of subjects: 439

Group type: COMPARATOR
Intervention: CBT (cognitive-behavioral therapy)
Number of subjects: 439
Study: 12658672

Group type: EXPERIMENTAL
Intervention: Group CBT with spouse involvement
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Standard group CBT
Number of subjects: 94

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 94
Study: 10733540

Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg twice per day) for 1 week
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 46
Study: 8958194

Group type: EXPERIMENTAL
Intervention: Method A
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Method SP
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Method SW
Number of subjects: 29
Study: 1326405

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg
Number of subjects: 1

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 1
Study: 2866493

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 66
Study: 31277049

Group type: EXPERIMENTAL
Intervention: ICU acquired Weakness (ICUaW) patients
Number of subjects: 36
Study: 29076666

Group type: EXPERIMENTAL
Intervention: Topical Capsaicin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Topical Turpentine Oil
Number of subjects: 300
Study: 26054444

Group type: EXPERIMENTAL
Intervention: Health education booklet and telephone follow-ups
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study: 23809982

Group type: EXPERIMENTAL
Intervention: SS + rSK 200,000 IU
Number of subjects: 80

Group type: COMPARATOR
Intervention: SS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SS + rSK 100,000 IU
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 21639940

Group type: EXPERIMENTAL
Intervention: My Parenting SOS intervention (35-week program with 12 sessions focusing on parenting skills and promoting healthier eating and physical activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: My Parenting SOS intervention
Number of subjects: 0
Study: 19349130

Group type: EXPERIMENTAL
Intervention: Carbosylane (activated charcoal-simethicone combination)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 16384767

Group type: EXPERIMENTAL
Intervention: 1% lidocaine with epinephrine buffered with sodium bicarbonate
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1% lidocaine freshly mixed with epinephrine
Number of subjects: 60
Study: 12767537

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard antiarrhythmics (Lidocaine and Amiodarone)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (subgroup analysis)
Number of subjects: 100
Study: 11065207

Group type: EXPERIMENTAL
Intervention: 100% oxygen (O2 group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 33% oxygen in nitrous oxide (O2‐N2O group)
Number of subjects: 40
Study: 9412397

Group type: EXPERIMENTAL
Intervention: Amoxycillin/potassium clavulanate (amoxyclav) 1.2 g IV every 8 hours for 2 days, then 625 mg orally thrice a day for 5 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cefotaxime 1.0 g IM every 8 hours for 7 days
Number of subjects: 20